Zepbound vs Liraglutide: Switching Between Them

How Do Zepbound and Liraglutide Actually Work?

Zepbound and liraglutide both activate the GLP-1 receptor, but they do so through different mechanisms and with different receptor targets. Understanding the pharmacology explains why the efficacy gap between them is so large. Liraglutide is a single-receptor agonist. Zepbound adds a second receptor target that amplifies weight-loss signaling.

Liraglutide: GLP-1 Receptor Agonism Only

Liraglutide is a GLP-1 receptor agonist with 97% amino acid homology to native human GLP-1 1. It slows gastric emptying, suppresses appetite via hypothalamic signaling, and stimulates glucose-dependent insulin secretion. Half-life is approximately 13 hours, which is why it requires daily injections. The FDA approved the 3.0 mg/day formulation (Saxenda) for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity 2.

Tirzepatide (Zepbound): Dual GIP and GLP-1 Agonism

Tirzepatide is a single peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor 3. GIP receptor activation appears to enhance the anorectic effects of GLP-1 signaling and may reduce GI side effects compared with pure GLP-1 agonism at equivalent efficacy doses. The half-life of tirzepatide is approximately five days, enabling once-weekly dosing. The FDA approved Zepbound (tirzepatide) for chronic weight management in December 2023 4.

Efficacy Comparison: What the Trial Data Show

No published head-to-head randomized controlled trial has directly compared tirzepatide against liraglutide for weight loss in people without diabetes. The comparison below synthesizes the best available evidence from each drug's own key trial. These trials used similar eligibility criteria, making indirect comparison reasonable, though not equivalent to a direct RCT.

SURMOUNT-1: The Tirzepatide Weight-Loss Benchmark

SURMOUNT-1 enrolled 2,539 adults without diabetes who had a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity 3. Participants received tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks alongside lifestyle counseling.

Key results from SURMOUNT-1:

• Mean weight loss at 72 weeks: 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg versus 3.1% with placebo (P<0.001 for all doses) 3.
• 37.0% of participants on 15 mg achieved at least 25% body-weight reduction 3.
• Waist circumference decreased by a mean of 14.4 cm in the 15 mg group.

The New England Journal of Medicine published SURMOUNT-1 in 2022, and it remains the largest key trial for a non-GLP-1-only obesity medication to date 3.

SCALE Obesity: The Liraglutide Benchmark

SCALE Obesity enrolled 3,731 adults without diabetes who had a BMI ≥30 kg/m² or ≥27 kg/m² with dyslipidemia or hypertension 5. Participants received liraglutide 3.0 mg/day or placebo for 56 weeks alongside a reduced-calorie diet and increased physical activity.

Key results from SCALE Obesity:

• Mean weight loss at 56 weeks: 8.0% with liraglutide 3.0 mg versus 2.6% with placebo (P<0.001) 5.
• 63.2% of liraglutide participants lost at least 5% of body weight versus 27.1% on placebo 5.
• Liraglutide produced significant improvements in waist circumference and cardiometabolic risk markers.

Side-by-Side Numbers

| Metric | Zepbound 15 mg (SURMOUNT-1) | Liraglutide 3 mg (SCALE Obesity) | |---|---|---| | Trial duration | 72 weeks | 56 weeks | | Trial N | 2,539 | 3,731 | | Mean weight loss | 20.9% | 8.0% | | ≥5% weight loss responders | 91% | 63.2% | | Dosing frequency | Once weekly | Once daily | | Route | Subcutaneous injection | Subcutaneous injection |

The efficacy difference is substantial. Zepbound at maximum dose produced approximately 2.6 times the mean weight loss seen with liraglutide in these trials. That gap reflects both the additional GIP receptor activity and the longer duration of the SURMOUNT-1 trial.

Is Zepbound Better Than Liraglutide?

For weight loss in adults without type 2 diabetes, the available evidence consistently favors tirzepatide over liraglutide on every measured efficacy endpoint. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "for patients who require greater weight loss, agents with the largest efficacy data should be prioritized" 6. Tirzepatide meets that standard more fully than liraglutide.

Where Liraglutide Still Has a Role

Liraglutide is not obsolete. Several clinical situations make it a reasonable first or ongoing choice:

• Insurance coverage or cost. The FDA approved the first generic liraglutide (Novo Nordisk's authorized generic Saxenda equivalent) in 2024, dropping monthly costs significantly below Zepbound's list price of approximately $1,059/month 7.
• Longer safety record. Liraglutide has been available since 2010 (Victoza for type 2 diabetes) and since 2014 (Saxenda for obesity), giving clinicians over a decade of real-world safety data 2.
• Daily titration control. Some patients or clinicians prefer daily dosing to modulate GI side effects more granularly than a weekly injection allows.
• Cardiovascular outcome data in type 2 diabetes. The LEADER trial (N=9,340) demonstrated that liraglutide reduced major adverse cardiovascular events by 13% versus placebo in patients with type 2 diabetes and high cardiovascular risk (hazard ratio 0.87, 95% CI 0.78 to 0.97) 8.

For patients primarily focused on maximum weight reduction with once-weekly convenience, Zepbound outperforms liraglutide by a wide margin.

Switching From Liraglutide to Zepbound

The more common clinical scenario is a patient already on liraglutide who wants to transition to tirzepatide because of inadequate weight loss. No FDA-approved labeling defines a specific switching protocol. The approach below reflects consensus from published clinical guidance and specialist practice.

Why Patients Switch

Liraglutide users who have been on maximum dose (3 mg/day) for 16 or more weeks and have not achieved at least 5% body-weight loss are considered non-responders by the criteria used in SCALE Obesity 5. Even responders sometimes switch because tirzepatide offers a substantially higher weight-loss ceiling at the 10 mg and 15 mg doses.

The Practical Switching Protocol

Step 1. Stop liraglutide. Because liraglutide's half-life is approximately 13 hours, it clears the receptor within 48 to 72 hours. Most clinicians allow one to seven days between the last liraglutide dose and the first tirzepatide injection to let any acute GI symptoms from liraglutide resolve.

Step 2. Start tirzepatide at the initiation dose. The FDA-approved starting dose of Zepbound is 2.5 mg subcutaneously once weekly for four weeks 4. Patients coming off liraglutide should not start at a higher dose to "match" their previous exposure. Both drugs work at the same GLP-1 receptor, so beginning at 2.5 mg still carries meaningful GI risk for someone who was GLP-1-sensitized.

Step 3. Titrate per standard schedule. Zepbound increases by 2.5 mg every four weeks as tolerated, up to a maximum of 15 mg weekly 4. Most patients reach their maintenance dose between week 20 and week 28.

Step 4. Monitor weight and GI symptoms at each dose step. Nausea, vomiting, and diarrhea are the most common adverse events with both drugs. In SURMOUNT-1, nausea occurred in 30.5% of tirzepatide participants 3. Prior liraglutide exposure does not appear to protect against or worsen tirzepatide GI side effects, but clinicians should reassess at each titration.

Switching From Zepbound to Liraglutide

Switching from tirzepatide back to liraglutide is less common but does occur. Reasons include cost constraints, insurance formulary changes, or a patient who finds weekly injections difficult and prefers daily dosing for behavioral or scheduling reasons.

Key Pharmacological Consideration

Tirzepatide's five-day half-life means it remains pharmacologically active for approximately three to four weeks after the last dose. Starting liraglutide too soon after the final tirzepatide injection may stack GLP-1 receptor stimulation and increase GI side effects. A washout of at least seven days after the last tirzepatide dose is a reasonable minimum. Some clinicians wait 14 days in patients with a history of severe GI intolerance.

Dose Selection for Liraglutide After Zepbound

Begin liraglutide at the standard titration starting dose of 0.6 mg/day for one week, then increase by 0.6 mg weekly up to the target of 3.0 mg/day, following the prescribing information 2. Do not start at 3.0 mg/day even if the patient was tolerating tirzepatide 15 mg, because the two drugs' receptor activation profiles differ enough that GI response is not predictable.

Expect Some Weight Regain

Weight regain is a documented outcome when any potent GLP-1-based therapy is stopped or down-titrated. The SURMOUNT-4 trial showed that participants who discontinued tirzepatide after 36 weeks of treatment regained an average of 14.8 percentage points of body weight over the following 52 weeks 9. Switching to liraglutide rather than stopping entirely will partially attenuate regain, but patients should expect to lose some of the weight reduction they achieved on tirzepatide.

GI Side Effects: Comparing the Two Drugs During a Switch

GI tolerability is the primary clinical concern during any GLP-1 transition. Both drugs share the same mechanism-related GI effects: nausea, vomiting, diarrhea, and constipation.

Incidence Data From Key Trials

In SURMOUNT-1, GI adverse events leading to discontinuation occurred in 4.3% of participants on tirzepatide 15 mg 3. In SCALE Obesity, GI adverse events led to discontinuation in 9.9% of liraglutide participants 5. The higher discontinuation rate with liraglutide may reflect the faster titration schedule used in the SCALE trial design rather than an intrinsic tolerability difference between the two molecules.

Managing GI Symptoms During the Switch

• Take injections with a small meal rather than fasting to slow absorption of any co-ingested food and reduce peak nausea.
• Avoid high-fat, high-sugar meals in the 24 hours after each injection.
• Oral ondansetron 4 mg as needed may be prescribed for breakthrough nausea during the first four to eight weeks of a new agent.
• If nausea is grade 3 or higher (unable to eat), pause titration and remain at the current dose for an additional four weeks before increasing.

Diabetes Status Changes the Calculus

Both drugs are approved for obesity management in people without diabetes. Both also have diabetes indications (Mounjaro for tirzepatide, Victoza for liraglutide). If a patient's glycemic status changes during treatment, the appropriate drug and dose may also change.

If a Patient Develops Type 2 Diabetes on Liraglutide

Liraglutide 1.2 mg or 1.8 mg/day (Victoza) is FDA-approved for type 2 diabetes management, but the 3.0 mg obesity dose is not labeled for glycemic control 2. A patient developing type 2 diabetes while on Saxenda 3.0 mg may benefit from switching to tirzepatide (Mounjaro), which carries both a weight-loss and a type 2 diabetes indication and has shown A1c reductions of up to 2.58 percentage points in the SURPASS-2 trial (N=1,879) 10.

Cardiovascular Risk Profile

The LEADER trial established liraglutide's cardiovascular benefit in high-risk type 2 diabetes patients 8. The SURMOUNT-MMO trial, which will assess tirzepatide's cardiovascular outcomes, was ongoing as of early 2025. Patients with established atherosclerotic cardiovascular disease and type 2 diabetes have the strongest evidence base for liraglutide's cardiovascular benefit at this time. That evidence gap should factor into switching decisions for this subgroup.

Cost and Access: A Practical Driver of Switching Decisions

Cost is frequently what drives a switch in either direction, and it deserves clinical attention rather than being left entirely to pharmacy benefit teams.

Current Cost Field

Zepbound's list price is approximately $1,059 per month without insurance coverage 11. Liraglutide's generic (authorized generic 3.0 mg/day injection) entered the U.S. Market in 2024 following FDA approval, reducing monthly costs substantially. Compounded tirzepatide is available through FDA-registered outsourcing facilities during periods of shortage, but the FDA has noted that tirzepatide shortage designation ended in late 2024, which may restrict compounding access going forward 12.

Insurance Formulary Patterns

Most commercial insurers that cover Zepbound require prior authorization demonstrating a BMI ≥30 kg/m² and documented failure of lifestyle intervention. Step therapy requirements at some plans mandate a trial of a lower-cost GLP-1 agent, which may mean liraglutide must be tried first. Clinicians should document the reason for switching in clinical notes to support prior authorization appeals.

What Clinicians Are Saying

The Endocrine Society's 2023 Clinical Practice Guideline on Pharmacological Management of Obesity states: "Clinicians should offer pharmacotherapy in addition to lifestyle modifications to adults with obesity who are ready to begin pharmacotherapy to promote greater weight loss and weight-loss maintenance, with a preference for agents with the highest efficacy and most favorable safety profile." 6

The American Gastroenterological Association's 2022 rapid clinical practice update on obesity pharmacotherapy notes that "tirzepatide's dual mechanism offers a meaningful clinical advance over agents targeting GLP-1 alone" 13.

Monitoring After Any Switch

Lab and clinical monitoring should be standardized regardless of which direction the switch goes.

Recommended Monitoring Schedule

• Baseline before switching: Weight, BMI, fasting glucose, HbA1c, LFTs, lipid panel, blood pressure, heart rate.
• 4 weeks after starting the new drug: Weight, GI symptom assessment, blood pressure, heart rate.
• 12 weeks after starting: Weight, fasting glucose, HbA1c if diabetic or prediabetic, review of dose titration progress.
• 24 weeks: Full metabolic panel, lipid panel, weight. Assess whether the patient has achieved at least 5% body-weight loss. If not, re-evaluate the treatment plan.

The FDA prescribing information for both agents recommends discontinuing treatment if a patient has not achieved at least 4% to 5% weight loss after 16 weeks at the maintenance dose 2 4.